CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer

Yumin Xia, Gaurav K. Gupta, Ana P. Castano, Pawel Mroz, Pinar Avci, Michael R. Hamblin

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Breast cancer is the most common cause of cancer death in women. The side effects and complications following current breast cancer therapy can be devastating. Moreover, the prognosis in late stages of the diseases is usually poor. Photodynamic therapy (PDT) is a promising cancer treatment modality that is capable of both local tumor destruction and immune stimulation. However, treatment with PDT alone is often non-curative due to tumor-induced immune cell dysfunction and immune suppression. This phenomenon has motivated a new approach by combining immunostimulants with PDT to enhance anti-tumor immunity. In the present study, we investigated PDT mediated by verteporfin and 690 nm light delivered 15 min later, in combination with an immunomodulation approach using CpG oligodeoxynucleotide for the treatment of 4T1 metastatic breast cancer in a BALB/c immunocompetent mouse model. In vitro, CpG primed immature dendritic cells (DC) via toll like receptor 9 to phagocytose PDT killed tumor cells leading to DC maturation and activation. Peritumoral injection of CpG after PDT in mice gave improved local tumor control and a survival advantage compared to either treatment alone (p < 0.05). CpG may be a valuable dendritic cell targeted immunoadjuvant to combine with PDT.

Original languageEnglish (US)
Pages (from-to)897-905
Number of pages9
JournalJournal of Biophotonics
Volume7
Issue number11-12
DOIs
StatePublished - Jan 1 2014

Fingerprint

Photodynamic therapy
Oligodeoxyribonucleotides
Photochemotherapy
breast
therapy
cancer
Breast Neoplasms
Tumors
tumors
Neoplasms
Dendritic Cells
Immunologic Adjuvants
cells
mice
Toll-Like Receptor 9
Therapeutics
Oncology
Immunomodulation
prognosis
Phagocytosis

Keywords

  • Breast cancer
  • CpG oligodeoxynucleotide
  • Dendritic cells
  • Photodynamic therapy

Cite this

CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. / Xia, Yumin; Gupta, Gaurav K.; Castano, Ana P.; Mroz, Pawel; Avci, Pinar; Hamblin, Michael R.

In: Journal of Biophotonics, Vol. 7, No. 11-12, 01.01.2014, p. 897-905.

Research output: Contribution to journalArticle

Xia, Yumin ; Gupta, Gaurav K. ; Castano, Ana P. ; Mroz, Pawel ; Avci, Pinar ; Hamblin, Michael R. / CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer. In: Journal of Biophotonics. 2014 ; Vol. 7, No. 11-12. pp. 897-905.
@article{8817ee7648cb4038afbd33fe95d1afa6,
title = "CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer",
abstract = "Breast cancer is the most common cause of cancer death in women. The side effects and complications following current breast cancer therapy can be devastating. Moreover, the prognosis in late stages of the diseases is usually poor. Photodynamic therapy (PDT) is a promising cancer treatment modality that is capable of both local tumor destruction and immune stimulation. However, treatment with PDT alone is often non-curative due to tumor-induced immune cell dysfunction and immune suppression. This phenomenon has motivated a new approach by combining immunostimulants with PDT to enhance anti-tumor immunity. In the present study, we investigated PDT mediated by verteporfin and 690 nm light delivered 15 min later, in combination with an immunomodulation approach using CpG oligodeoxynucleotide for the treatment of 4T1 metastatic breast cancer in a BALB/c immunocompetent mouse model. In vitro, CpG primed immature dendritic cells (DC) via toll like receptor 9 to phagocytose PDT killed tumor cells leading to DC maturation and activation. Peritumoral injection of CpG after PDT in mice gave improved local tumor control and a survival advantage compared to either treatment alone (p < 0.05). CpG may be a valuable dendritic cell targeted immunoadjuvant to combine with PDT.",
keywords = "Breast cancer, CpG oligodeoxynucleotide, Dendritic cells, Photodynamic therapy",
author = "Yumin Xia and Gupta, {Gaurav K.} and Castano, {Ana P.} and Pawel Mroz and Pinar Avci and Hamblin, {Michael R.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/jbio.201300072",
language = "English (US)",
volume = "7",
pages = "897--905",
journal = "Journal of Biophotonics",
issn = "1864-063X",
publisher = "Wiley-VCH Verlag",
number = "11-12",

}

TY - JOUR

T1 - CpG oligodeoxynucleotide as immune adjuvant enhances photodynamic therapy response in murine metastatic breast cancer

AU - Xia, Yumin

AU - Gupta, Gaurav K.

AU - Castano, Ana P.

AU - Mroz, Pawel

AU - Avci, Pinar

AU - Hamblin, Michael R.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Breast cancer is the most common cause of cancer death in women. The side effects and complications following current breast cancer therapy can be devastating. Moreover, the prognosis in late stages of the diseases is usually poor. Photodynamic therapy (PDT) is a promising cancer treatment modality that is capable of both local tumor destruction and immune stimulation. However, treatment with PDT alone is often non-curative due to tumor-induced immune cell dysfunction and immune suppression. This phenomenon has motivated a new approach by combining immunostimulants with PDT to enhance anti-tumor immunity. In the present study, we investigated PDT mediated by verteporfin and 690 nm light delivered 15 min later, in combination with an immunomodulation approach using CpG oligodeoxynucleotide for the treatment of 4T1 metastatic breast cancer in a BALB/c immunocompetent mouse model. In vitro, CpG primed immature dendritic cells (DC) via toll like receptor 9 to phagocytose PDT killed tumor cells leading to DC maturation and activation. Peritumoral injection of CpG after PDT in mice gave improved local tumor control and a survival advantage compared to either treatment alone (p < 0.05). CpG may be a valuable dendritic cell targeted immunoadjuvant to combine with PDT.

AB - Breast cancer is the most common cause of cancer death in women. The side effects and complications following current breast cancer therapy can be devastating. Moreover, the prognosis in late stages of the diseases is usually poor. Photodynamic therapy (PDT) is a promising cancer treatment modality that is capable of both local tumor destruction and immune stimulation. However, treatment with PDT alone is often non-curative due to tumor-induced immune cell dysfunction and immune suppression. This phenomenon has motivated a new approach by combining immunostimulants with PDT to enhance anti-tumor immunity. In the present study, we investigated PDT mediated by verteporfin and 690 nm light delivered 15 min later, in combination with an immunomodulation approach using CpG oligodeoxynucleotide for the treatment of 4T1 metastatic breast cancer in a BALB/c immunocompetent mouse model. In vitro, CpG primed immature dendritic cells (DC) via toll like receptor 9 to phagocytose PDT killed tumor cells leading to DC maturation and activation. Peritumoral injection of CpG after PDT in mice gave improved local tumor control and a survival advantage compared to either treatment alone (p < 0.05). CpG may be a valuable dendritic cell targeted immunoadjuvant to combine with PDT.

KW - Breast cancer

KW - CpG oligodeoxynucleotide

KW - Dendritic cells

KW - Photodynamic therapy

UR - http://www.scopus.com/inward/record.url?scp=84934295247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84934295247&partnerID=8YFLogxK

U2 - 10.1002/jbio.201300072

DO - 10.1002/jbio.201300072

M3 - Article

VL - 7

SP - 897

EP - 905

JO - Journal of Biophotonics

JF - Journal of Biophotonics

SN - 1864-063X

IS - 11-12

ER -